# GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers

> **NCT01118975** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Maryland, Baltimore** · enrollment: 12 (actual)

## Conditions studied

- Breast Cancer
- Neoplasm Metastasis

## Interventions

- **DRUG:** Vorinostat
- **DRUG:** Lapatinib

## Key facts

- **NCT ID:** NCT01118975
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Lost sponsorship for study drug
- **Last updated:** 2019-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01118975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01118975, "GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT01118975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*